Collection Periodical Articles [327/330] Books/Book Section [1/1] Conference Papers/Meeting Abstract [115/179] Siblings Winston C.Y. Yu [19/19] Ko-Jiunn Liu [85/98] Tsang-Wu Liu [119/125] Jieh-Yuan Liou(2003-2010) [3/3] Her-Shyong Shiah(1996-2012) [26/31] Shine-Gwo Shiah [51/54] Nai-Jung Chiang [82/94] Hui-Ju Mandy Ch'ang [39/44] Jang-Yang Chang [234/254] Kwang-Yu Chang [69/79] I-Shou Chang [103/106] Wun-Shaing Wayne Chang [52/53] Jeffrey Shu-Ming [89/91] Jacqueline Whang-Peng(1996-2007) [120/126] Neng-Yao Shih [37/43] Chia-Huei Lee [29/29] Alan Yueh-Luen Lee [48/49] Su-Fang Lin [32/32] Yi-Hsin Yang [41/42] Shih-Sheng Jiang [88/90] Che-Hung Shen [14/16] Wen-Chun Hung [88/88] Shuang-En Chuang [82/91] Kelvin Kun-Chih Tsai [32/34] Hui-Jen Tsai [66/71] Yung-Yeh Su [40/40] Jen-Liang Su [24/25] Ching-Chuan Kuo [71/76] Shang-Hung Chen [45/48] Jen-Yang Chen [72/72] Mei-Shya Chen(2002-2009) [1/1] Shih-Cheng Chen [2/2] Ya-Wen Chen [38/39] Tze-Sing Huang [55/55] Dau-Yang Huang [26/26] Chou-Chik George Ting(2000-2004) [5/5] Others [464/471] Ming Jacqueline Liu(1996-2007) [60/62] Mei-Ying Liu(2004-2006) [2/2] Cheng-Wen Wu(1996-2008) [53/55] Szu-Wen Tseng(1997-2007) [4/4] Kuan-Te Li(1997-2004) [4/6] Ching-Tai Lin(1999-2007) [5/5] Wen-Kuang Yang(1996-1999) [21/21] Chuan-Cheng Wang(1996-2003) [4/4] Shin-Hun P. Juang(1997-2004) [11/11] Tzung-Huang Jan(2000-2008) [2/2] Gi-Ming Lai(2004-2008) [41/47] Li-Jung Juan(2000-2006) [6/7] Jim-Ray Chen(2003-2007) [6/6] Yen-Ying Ma(1997-1999) [1/1] Chi-Ying F. Huang(2005-2007) [9/10] Community Statistics Item counts issued in 3 years:74(14.51%) Items With Fulltext:443(86.86%) Download counts of the item Download times greater than 0:443(100.00%) Download times greater than 100:425(95.94%) Total Bitstream Download Counts:177337(3.31%) Last Update: 2024-11-28 17:46 Top Upload Loading... Top Download Loading... Recent Submissions Pan-Asian adapted ESMO clinical pra... Nivolumab plus chemotherapy in pati... Survival of advanced/recurrent gast... Topiramate suppresses peri-infarct ... A phase 1 study of biweekly nab-pac... Plain language summary of the FOENI... Outcomes of post-immunotherapy dura... Durvalumab or placebo plus gemcitab... Impact of previous S-1 treatment on... Chromatin remodeling-related PRDM1 ...

Jump to a point in the index: (Choose year) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (Choose month) January February March April May June July August September October November December Or type in a year:

Ordering With Most Recent First Show Oldest First

Showing items 251-275 of 510. (21 Page(s) Totally) << < 6 7 8 9 10 11 12 13 14 15 > >> View [10|25|50] records per page

Date	Title	Relation
2016-10	Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor	Cancer Research and Treatment. 2016 Oct;48(4):1155-1166.
2016-10	BPR1J373, an oral multiple tyrosine kinase inhibitor, targets c-KIT for the treatment of c-KIT driven myeloid leukemia	Molecular Cancer Therapeutics. 2016 Oct;15(10):2323-2333.
2016-10	Effects of nanoliposomal irinotecan (nal-IRI;MM-398) +/- 5-Fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-b	Oncology Research and Treatment. 2016 Oct;39(Suppl. 3):259.
2016-10	Quality-adjusted time without symptoms or toxicity (Q-TWIST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucavorin (5-FU/LV) vs 5-FU/LV alone in patients with metastatic pancreatic adenocarcinoma (mPAC) previously treated with ge	Oncology Research and Treatment. 2016 Oct;39(Suppl. 3):260.
2016-10	Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy	Annals of Oncology. 2016 Oct;27(Suppl. 6):Meeting Abstract 622PD.
2016-10	Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based ther	Annals of Oncology. 2016 Oct;27(Suppl. 6):Meeting Abstract 693P.
2016-10	CagA and NFAT co-operatively participate in the lymphomagenesis of gastric MALT lymphoma	Annals of Oncology. 2016 Oct;27(Suppl. 6):Meeting Abstract 933P.
2016-09	The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer	Oncotarget. 2016 Sep;7(38):61136-61151.
2016-09	Effects of nanoliposomal irinotecan (nal-IRI; MM-398) +/- 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: Results from t	Annals of Oncology. 2016 Sep;27(Suppl. 4):Meeting Abstract B04.
2016-08	Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma	Journal of Hepatology. 2016 Aug;65(2):296-304.
2016-07	Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer	Expert Opinion on Pharmacotherapy. 2016 Jul;17(10):1413-1420.
2016-06	Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): A randomized, open-label phase 2 study	Annals of Oncology. 2016 Jun;27(Suppl. 2):ii84.
2016-06	Effects of nal-IRI (MM-398) +/- 5-fluorouracil on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine	Annals of Oncology. 2016 Jun;27(Suppl. 2):119.
2016-06	Safety across subgroups in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy	Annals of Oncology. 2016 Jun;27(Suppl. 2):110.
2016-05-14	Nanoliposomal irinotecan in metastatic pancreatic cancer - Authors' reply	Lancet. 2016 May 14-20;387(10032):1997.
2016-05-03	Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer	Scientific Reports. 2016 May 3;6:Article number 25369.
2016-05	Overexpression of regulator of G protein signaling 11 promotes cell migration and associates with advanced stages and aggressiveness of lung adenocarcinoma	Oncotarget. 2016 May;7(21):31122-31136.
2016-05	Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine	Journal of Clinical Oncology. 2016 May;34(15, Suppl.):Meeting Abstract 4126.
2016-05	Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1: A randomized phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy	Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e15740.
2016-05	Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC)	Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number 4017.
2016-05	Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI; MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with	Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e15732.
2016-05	Efficacy of frontline antibiotics therapy in the treatment of Helicobacter pylori-negative gastric low-grade mucosa-associated lymphoid tissue lymphoma	Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e19024.
2016-03	miR-520h is crucial for DAPK2 regulation and breast cancer progression	Oncogene. 2016 Mar 3;35(9):1134-1142.
2016-03	Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer	Oncogene. 2016 May;35(12):1517-1528.
2016-02	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial	Lancet. 2016 Feb;387(10018):545-557.

Showing items 251-275 of 510. (21 Page(s) Totally) << < 6 7 8 9 10 11 12 13 14 15 > >> View [10|25|50] records per page